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A B S T R A C T
Purpose
Cardiovascular diseases are increasingly recognized as late effects of Hodgkin lymphoma (HL) treat-
ment. The purpose of this study was to identify the risk factors for coronary heart disease (CHD) and to
quantify the effects of radiation dose to the heart, chemotherapy, and other cardiovascular risk factors.
Patients and Methods
We conducted a nested case-control study in a cohort of 2,617 5-year HL survivors, treated between
1965 and 1995. Caseswere patients diagnosedwith CHD as their first cardiovascular event after HL.
Detailed treatment informationwas collected frommedical records of 325 cases and 1,204matched
controls. Radiation charts and simulation radiographs were used to estimate in-field heart volume
and mean heart dose (MHD). A risk factor questionnaire was sent to patients still alive.
Results
The median interval between HL and CHD was 19.0 years. Risk of CHD increased linearly with
increasing MHD (excess relative risk [ERR]) per Gray, 7.4%; 95% CI, 3.3% to 14.8%). This results in a
2.5-fold increased risk of CHD for patients receiving a MHD of 20 Gy from mediastinal radiotherapy,
comparedwith patients not treatedwithmediastinal radiotherapy. ERRs seemed to decreasewith each
tertile of age at treatment (ERR/Gy,27.5years, 20.0%; ERR/Gy27.5-36.4years, 8.8%; ERR/Gy36.5-50.9years,
4.2%; Pinteraction = .149). Having $ 1 classic CHD risk factor (diabetes mellitus, hypertension, or
hypercholesterolemia) independently increased CHD risk (rate ratio, 1.5; 95%CI, 1.1 to 2.1). A high level
of physical activity was associated with decreased CHD risk (rate ratio, 0.5; 95% CI, 0.3 to 0.8).
Conclusion
The linear radiation dose-response relationship identified can be used to predict CHD risk for future
HL patients and survivors. Appropriate early management of CHD risk factors and stimulation of
physical activity may reduce CHD risk in HL survivors.
J Clin Oncol 34:235-243. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Hodgkin lymphoma (HL) treatment has improved
over recent decades, leading to a 10-year survival rate
of more than 80%.1 However, radiotherapy and
chemotherapy are associated with increased car-
diovascular morbidity and mortality in long-term
survivors.2-7 Although radiation doses and target
volumes have been reduced over the past decades,
mediastinal radiotherapy is still indicated for a
substantial proportion of patients,8,9 which may
result in considerable radiation exposure of the heart.
Few studies have examined the dose-response
relationship for cardiac radiation and risk of cor-
onary heart disease (CHD) after radiotherapy. A
recent study by Darby et al10 showed a linear dose-
response relationship between radiation dose to
the heart and CHD risk in breast cancer survivors
for a relatively low range of mean heart dose
(MHD) (range, 0.03-27.7 Gy; average, 5 Gy). The
shape of the dose-response relationship has not
been studied in HL patients, who generally receive
much higher MHDs and are usually younger at
diagnosis than breast cancer patients.
Schellong et al11 and Mulrooney et al12 ob-
served an association between cardiovascular dis-
eases and prescribed mediastinal radiation dose
and MHD among childhood HL (and other
cancer) survivors; however, the shape of the
radiation dose-response relationship and excess
relative risks (ERRs) were not described.
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In addition to the shape of the dose-response relationship, the
roles of established cardiovascular disease risk factors and lifestyle
on CHD risk have rarely been studied among HL survivors.4,5,13
Therefore, the aim of this study was to assess the shape of the dose-
response curve for cardiac radiation dose and the risk of CHD in
adolescent and adult HL survivors and to investigate the role of
chemotherapy, lifestyle, and other established cardiovascular dis-
ease risk factors.
PATIENTS AND METHODS
Study Population
We conducted a nested case-control study in an existing cohort (N =
2,617) of HL survivors treated in the Netherlands between 1965 and 1995.
The cohort was derived from hospital-based cancer registries of four large
university hospitals and one cancer center. Details on patient selection and
data collection have been published previously.2,7,12,14-17 Patients were
eligible for this study if (1) they survived$ 5 years after HL diagnosis; (2)
they were diagnosed with HL before the age of 51 years; (3) HL was their
first primary malignancy, except for nonmelanoma skin cancer or car-
cinoma in situ of the cervix uteri or the breast; and (4) radiotherapy for HL
was the only radiotherapy given to the neck or trunk before the cutoff date,
which was defined as the date of CHD for the cases or the date of HL
diagnosis plus a time interval equal to the interval from the date of HL
diagnosis to the date of CHD diagnosis of the corresponding case for
matched controls.
Cases and Controls
Cases (n = 325) were patients who developed CHD in the form of
either symptomatic myocardial infarction or angina pectoris requiring
intervention (Common Terminology Criteria for Adverse Events, version
4.0, grade $ 2; Appendix Text A1, online only)18 as their first clinically
significant heart disease. Cases were identified from medical records or
postal questionnaires completed by their general practitioners. Follow-up
was complete up to October 2013. For each case with CHD, we attempted
to select four controls from the cohort, individually matched on sex, age at
HL diagnosis (# 1 year), and date of HL diagnosis (# 3 years). Controls
had to be free of any cardiac disease grade $ 2 at the cutoff date. In total,
1,204 controls were matched to the cases.
Data Collection
Detailed information on treatment (including radiation doses and
fields and cumulative doses of cytotoxic drugs), medical history, medi-
cation use, smoking, and established cardiovascular risk factors at both
diagnosis of HL and during follow-up was collected from medical records
and radiation charts. In addition, a questionnaire on established car-
diovascular risk factors and lifestyle was mailed to all patients still alive in
2013 (n = 475) in three of the five centers (response rate, 70%). Patients
were defined as having a risk factor when the risk factor concerned was
diagnosed before CHD or the cutoff date. The ethics review board of the
Netherlands Cancer Institute approved this study.
Mean Heart Dose
TheMHDwas assessed using the percentage of cardiac volumewithin
field (%CVWF) method19 and converted to equivalent dose in 2-Gy
fractions (EQD2).20 We recently showed that this method gives reliable
MHD estimates for our patient population and compares well with MHD
based on computed tomography (CT)-based dosimetry.19 We outlined the
cardiac contour on the HL simulation radiographs to obtain the %CVWF.
Additional details can be found in Appendix Text A2.
When original radiotherapy charts were unavailable, information
about radiotherapy, including dates, anatomic areas, dose, fractionation,
and treatment energy, was abstracted from clinical notes. We assigned an
average %CVWF to radiation-treated patients for whom no simulation
radiographs were available and an average prescribed dose to patients for
whom no prescribed dose was available (n = 473, including 105 cases), on
the basis of hospital, treatment period, and sex.
Statistical Analysis
Odds ratios for CHD for different levels of each factor were calculated
using conditional logistic regression on sets of individual cases and their
matched controls, and were interpreted as rate ratios (RRs). The Wald
method was used to calculate 95% CIs for factors with two levels. The
amount of information in each category, including the reference category
(so-called floating absolute risks), was used to calculate 95% CIs for factors
with more than two levels.21 Multivariable regression was used to assess
and control for confounding and to evaluate interactions between radi-
ation dose and other factors.
The dose-response relationship was estimated by modeling the CHD
rate as Km(1 + bd), where Km is a constant specific to eachmatched set, b is
the ERR of CHD per unit increase in dose, and d is the MHD of an
individual patient. Nonlinearity was evaluated by including an exponential
term: Km[1 + bd$exp(dd)]. Goodness of fit was assessed by likelihood ratio
tests. Interactions were evaluated using interaction terms and likelihood
ratio tests. Approximate cumulative incidence of CHD for categories of
MHD, with other heart disease or death as a competing risk, was estimated
from CHD RRs together with the cumulative risk of CHD for the entire
cohort, assuming that the distribution of all individuals in the cohort
across the dose categories was equal to that for the control patients.
Significance tests were two-sided and P # 0.05 was considered to
indicate statistical significance. Analyses were performed using STATA
statistical software (version 13.0; STATA, College Station, TX) and Epicure
(version 1.8; Hiro Soft International Inc, Seattle WA).
RESULTS
Characteristics of the 325 cases and 1,204 controls are described in
Table 1. The median age of patients was 32.2 years (interquartile
range [IQR], 24.4 to 39.6) at the time of HL diagnosis, and the
median interval between HL and CHDwas 19.0 years (IQR, 13.9 to
25.2). Myocardial infarction was diagnosed in 185 patients; angina
pectoris requiring intervention was diagnosed in 140 patients
(Appendix Table A1). In total, 169 of 325 cases died, 42.6% from a
cardiovascular disease, after a median follow-up period of 6.0 years
after their first CHD (Appendix Table A1). Thirty-one patients
died of their first CHD incident within a week.
Radiotherapy
Ninety-one percent of the cases had received mediastinal radi-
otherapy, given through parallel-opposed fields, compared with 79%
of the controls (Table 1). Mediastinal radiation therapy was associated
with a 2.63-fold increased risk of CHD (95%CI, 1.74 to 3.99; Table 2).
Para-aortic radiotherapy, with or without splenic radiation, was not
associated with CHD risk (RR, 0.99; 95% CI, 0.76 to 1.28).
The averageMHDwas 22.0 Gy for cases and 20.4 Gy for controls
(Table 1). A linear radiation dose-response relationship best described
the data, and no significant deviation from linearity was observed
(Pexponential-term = .356). The ERR for CHD increased by 7.4% per Gy
(95% CI, 3.3% to 14.8%; Fig 1), resulting in a 1.74-fold increased risk
at a MHD of 10 Gy (95% CI, 1.33 to 2.48) and a 2.48-fold increased
risk at a MHD of 20 Gy (95% CI, 1.66 to 3.96). The approximate 25-
year cumulative CHD incidence was 4.1% for patients with aMHD of
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0 Gy, 9.4% for patients with a MHD of 15 to 20 Gy, and 12.6% for
patients with aMHDof$ 25Gy (Fig 2). Results were similar whenwe
only included patients for whom the MHD was known (Appendix
Table A2). Cases had a median%CVWF of 66%, compared with 64%
for controls. Variation in %CVWF was limited, with interquartile
ranges of 57% to 71% and 55% to 70%, respectively (Table 1).
Other Treatment-Related Risk Factors
Chemotherapy was not associated with CHD risk (RR,
0.87; 95% CI, 0.67 to 1.13), nor were anthracycline-containing
chemotherapy (RR, 1.11, 95% CI, 0.76 to 1.62) or vincristine-
containing chemotherapy (RR, 0.86; 95% CI, 0.66 to 1.13), after
accounting for mediastinal radiotherapy. Splenectomy also
Table 1. Patient Demographics and Clinical Characteristics
Characteristic No. of Cases* % No. of Controls* %
Total 325 100 1,208 100
Sex
Men 236 72.6 889 73.9
Women 89 27.4 319 26.4
Age at diagnosis, years (median, IQR) 32.3 24.5-39.4 32.2 24.4-39.6
26 98 30.2 370 30.6
26-32 73 22.5 271 22.4
33-39 80 24.6 292 24.2
40-50 74 22.8 275 22.8
Year of diagnosis
1965-1974 116 35.7 429 35.5
1975-1984 124 38.2 513 32.5
1985-1995 85 26.2 266 22.0
Time to IHD/cutoff (median, IQR) 19.0 13.9-25.2 19.2 13.9-25.2
Smoking
Smoked at HL diagnosis 195 61.1 645 55.1
Smoking at end of follow-up 93 31.1 321 30.0
Ever smoked 236 74.0 820 69.7
Recent smoker at time of cutoff (, 5 years) 109 34.0 350 29.0
Unknown time of quitting smoking 77 23.7 251 20.8
Classic risk factors
Diabetes mellitus diagnosed before CHD/cutoff date 11 3.4 38 3.2
Hypercholesterolemia diagnosed before CHD/cutoff date 31 9.5 89 7.4
Hypertension diagnosed before CHD/cutoff date 54 16.6 122 10.1
Obesity at HL 16 5.2 33 3.0
Obesity at end of follow-up (BMI $ 30 kg/m2) 106 36.3 288 27.3
At least one of the above risk factors 80 24.6 213 17.6
Treatment of HL†
Radiotherapy 315 96.9 1097 90.8
Subdiaphragmatic radiotherapy 157 48.3 573 47.4
Mediastinal radiotherapy 296 91.1 957 79.2
Chemotherapy 200 61.5 805 66.6
Alkylating CT 167 84.3 686 87.1
Procarbazine 139 42.9 614 50.9
Vincristine 135 41.7 585 48.5
Anthracyclines 68 21.0 226 18.7
Splenectomy 103 32.0 384 32.5
Prescribed mediastinal dose, Gy (median, IQR)‡ 33 29-37 33 29-38
0 29 8.9 251 20.8
15-24 5 1.5 28 2.3
25-34 26 8.0 98 8.1
35-39 156 48.0 537 44.5
40-45 109 33.5 294 24.3
Mean heart dose, Gy (median, IQR) 21.7 18.4-25.7 20.2 17.5-24.8
0 17 5.2 160 13.3
1-5 12 3.7 93 7.7
5-14 19 5.9 80 6.6
15-1y 71 21.8 242 20.0
20-24 102 31.4 332 27.5
25-34 99 30.5 280 23.2
35-45 5 1.5 21 1.7
Percent cardiac contour within field (median, IQR) 64 55-70 66 57-71
NOTE. All patients were treated with parallel-opposed fields.
Abbreviations: BMI, bodymass index; CHD, coronary heart disease; CT, computed tomography; HL, Hodgkin lymphoma; IHD, ischemic heart disease; IQR, interquartile
range.
*Two-hundred fifty-six cases had four controls, 48 cases had three controls, 15 cases had two controls, and six cases had only one control.
†Treatment variables are not mutually exclusive.
‡Prescribed dose was missing for five cases and 19 controls, simulation radiographs were missing for 84 cases and 271 controls, and both were missing for 16 cases
and 78 controls. Imputation was on the basis of hospital, sex, and treatment period.
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did not affect CHD risk (RR, 0.91; 95% CI, 0.68 to 1.22;
Table 2).
Patient-Related Risk Factors
Twenty-five percent of cases had at least one classic car-
diovascular risk factor (diabetes mellitus, hypercholesterolemia, or
hypertension) diagnosed before the diagnosis of CHD (Table 1).
Only hypertension (RR, 1.85; 95% CI, 1.28 to 2.66) and the
presence of at least one risk factor (RR, 1.59; 95% CI, 1.17 to 2.19)
were associated with an increased risk of CHD (Table 3).When risk
factors were taken into account in a less conservative manner, that
is, by also including risk factors that were diagnosed around the
time of CHD diagnosis or cutoff date, not only hypertension but
also diabetes mellitus and hypercholesterolemia were associated
with a significantly increased risk of developing CHD (Appendix
Table A3). Obesity at the time of CHD diagnosis or the cutoff date
was associated with an increased risk of CHD as well (RR, 1.64;
95% CI, 1.24 to 2.16). Whereas ever smoking was not associated
with CHD risk, smoking within 5 years before a diagnosis of CHD
or the cutoff date was associated with an increased risk of CHD
(RR, 1.56; 95% CI, 1.13 to 2.15; Table 3). Patients with a high level
of physical activity at the time of the follow-up questionnaire (. 3
Table 2. Risk of Coronary Heart Disease According to Hodgkin Lymphoma Treatment
Treatment Factor
No. of Cases
(n = 325)
No. of Controls
(n = 1,204)
Crude
P
Adjusted*
PRR 95% CI RR 95% CI
Radiotherapy
No 10 111 1 ref 1 ref
Yes 315 1093 3.16 1.63 to 6.14 .001 2.99 1.52 to 5.85 .001
Mediastinal radiotherapy
No 29 251 1 ref 1 ref
Yes 296 953 2.71 1.79 to 4.08 , .001 2.63 1.74 to 3.99 , .001
Para-aortic radiotherapy
No 168 633 1 ref 1 ref
Yes 157 571 1.05 0.81 to 1.35 0.712 .99 0.76 to 1.28 .927
Splenic radiotherapy
No 229 878 1 ref 1 ref
Yes 96 326 1.13 0.86 to 1.50 .372 1.07 0.80 to 1.42 .656
Prescribed mediastinal dose, Gy
0 (no mediastinal radiotherapy) 29 251 1.00 0.68 to 1.48 1.00 0.67 to 1.48
15-24 5 28 1.49 0.57 to 3.89 1.51 0.58 to 3.96
25-34 26 97 2.31 1.50 to 3.57 2.30 1.49 to 3.56
35-39 156 535 2.56 2.12 to 3.08 2.52 2.10 to 3.03
40-45 109 293 3.12 2.50 to 3.90 , .001† 3.03 2.41 to 3.82 , .001†
Mean heart dose, Gy
0 17 160 1.00 0.60 to 1.66 1.00 0.60 to 1.67
1-5 12 93 1.19 0.65 to 2.19 1.14 0.62 to 2.10
5-14 19 80 2.16 1.30 to 3.60 2.14 1.28 to 3.58
15-19 71 239 2.83 2.16 to 3.71 2.76 2.10 to 3.59
20-24 102 332 2.90 2.32 to 3.63 2.79 2.23 to 3.49
25-34 99 279 3.35 2.64 to 4.26 3.21 2.52 to 4.09
35-45 5 21 2.62 0.99 to 6.90 , .001† 2.54 0.96 to 6.69 , .001†
Chemotherapy
No 125 402 1.00 ref 1 ref
Yes 200 802 0.79 0.61 to 1.02 .069 0.87 0.67 to 1.13 .298
Alkylating chemotherapy
No 159 532 1 ref 1 ref
Yes 166 673 0.80 0.62 to 1.04 .101 0.92 0.70 to 1.20 .519
Procarbazine
No 185 591 1 ref 1 ref
Yes 139 612 0.70 0.54 to 0.91 .008 0.82 0.63 to 1.07 .148
Vincristine
No 189 620 1 ref 1 ref
Yes 165 583 0.73 0.56 to 0.95 .020 0.86 0.66 to 1.13 .294
Anthracyclines
No 256 978 1 ref 1 ref
Yes 68 224 1.08 0.75 to 1.57 .670 1.11 0.76 to 1.62 .593
Splenectomy‡
No 219 794 1 ref 1 ref
Yes 103 384 1.00 0.75 to 1.33 .990 0.91 0.68 to 1.22 .521
NOTE. All patients were treated with parallel-opposed field. Boldface indicates statistically significant RRs.
Abbreviations: ref, reference category; RR, rate ratio.
*Radiation-related factors are adjusted for any chemotherapy. Chemotherapy factors are adjusted for mediastinal radiotherapy. Splenectomy was adjusted for
mediastinal radiotherapy and any chemotherapy.
† P for trend.
‡Total numbers of cases and controls may vary because of missing values or inclusion of only patients treated with mediastinal radiotherapy.
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h/wk of walking, cycling, or sports) had a considerably lower risk of
developing CHD than did patients who were inactive (, 1 h/wk;
RR, 0.52; 95% CI, 0.32 to 0.83; Table 3). Also, a first-degree family
history of CHD was an independent risk factor for CHD (RR, 2.87;
95% CI, 1.41 to 5.88; Table 3).
Interactions With Radiation
We found no evidence for statistically significant modification
of the effect of MHD on CHD risk by chemotherapy, sex, car-
diovascular disease risk factors, and recent smoking at HL diagnosis
(Appendix Table A4). ERRs seemed to be highest in the lowest tertile
of age at HL diagnosis (ERR,27.5years, 20.0%/Gy; 95% CI, 5.4% to
70.5%) and decreased for the middle (ERR27.5-36.4years, 8.8%/Gy;
95% CI, 2.6% to 22.9%) and third tertile (ERR36.5-50.9years, 4.2%/Gy;
95% CI, 0.6% to 11.1%), although this difference was not statistically
significant (Pinteraction = .149). Nevertheless, due to the lower back-
ground risk in patients treated at a young age, this higher relative risk
did not materialize in a higher cumulative incidence at similar follow-
up intervals after treatment (Fig 3).
DISCUSSION
To our knowledge, this study shows for the first time a linear dose-
response relationship for MHD and the risk of CHD in 5-year
survivors of HL. The overall risk of CHD increased by 7.4% per Gy
(95% CI, 3.3% to 14.8%), resulting in a 2.5-fold increased risk at a
MHD of 20 Gy. ERRs seemed to decrease with older age at treatment
(ERR,27.5years, 20.0%/Gy; ERR27.5-36.4years, 8.8%/Gy; ERR36.5-50.9years,
4.2%/Gy). Although other studies in childhood cancer and breast
cancer survivors10-12,22 also showed increased risks with higher
radiation exposure of the heart, to our knowledge, our study is the
first one with sufficient data to estimate the shape of the dose-
response curve for CHD among adolescent and adult HL survivors.
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We previously studied the dose-response relationship for
valvular heart disease risk after HL and observed an upward
curvature with an ERR of 2.5% per Gy for doses less than 30 Gy and
11.2% for doses of 36 to 40 Gy.23 Because the mechanisms
underlying the different types of heart damage after radiation
remain unclear, a different pathogenesis may underlie the shape of
the dose-response curve for valvular heart disease. Furthermore,
uncertainties in assessment of dose to relevant target structures
may add to the difference in findings.
Our results are consistent with the results of Darby et al,10 who
also observed a linear dose-response relationship for the risk of
major coronary events after radiotherapy for breast cancer. For the
patients most comparable with the patients in Darby’s article (ie,
those treated between 36 and 50 years of age), however, we found
an ERR of 4.2%/Gy, whereas Darby et al10 reported an ERR of
7.4%/Gy. Because the confidence intervals of the ERRs in both
studies overlap, it is likely that uncertainties in both data sets
partially explain the difference in the magnitude of the ERRs. Our
study and Darby’s study also differed in terms of study population.
Our study included both men and women, patients who were not
irradiated, and patients who generally received a higher MHD.
Furthermore, although breast cancer survivors frequently received
a high dose to a small volume of the heart, HL survivors treated in
the past generally received a relatively lower, more homogenous
dose to a larger cardiac volume.24,25
Although a previous study12 only showed increased risks of
CHD after a MHD exceeding 15 Gy, other studies,10,26 including
ours, indicate that there is no threshold dose. In future patients,
clinicians should carefully weigh the benefits of reducing the MHD
against potential risks of higher doses to other organs (ie, lungs and
breasts in young females). Importantly, improved radiation poli-
cies, including reduction of radiation fields and breath-holding
techniques, lead to MHDs of only 4 to 8 Gy.25,27,28
Unfortunately, we were unable to clearly separate the effect of
irradiated heart volume from the effects of MHD due to collin-
earity of the MHD and the %CVWF. However, the variation in
irradiated heart volume in our population was limited, both in the
total population as well as in specific categories of MHD (data not
shown). The variation that occurs in traditional mantle-field
irradiation mainly applies to variation in the irradiated volume
of the apex, whereas the left main artery generally lies within the
radiation field. There remains a gap in knowledge with respect to
the role of irradiated heart volume, which should be studied in
more depth to fully appreciate the consequences of irradiating a
large part of the heart with a lower dose versus irradiating a smaller
part of the heart with a high dose.
Neither chemotherapy in general nor specific chemo-
therapeutic agents were associated with CHD risk. Previously,
anthracycline-containing chemotherapy has been associated with
heart failure and, recently, with valvular heart disease,2,5,7,29 but not
with CHD. Swerdlow et al30 previously observed an association
between anthracycline- and vincristine-containing chemotherapy
and the risk of death from myocardial infarction. We could not
confirm these results.
In this study, we showed that hypertension, obesity, and recent
smoking are independent risk factors for the development of CHD
in HL survivors. Similar results have been published previously for
childhood cancer survivors by Armstrong et al, who showed that
survivors with one or more risk factors had a higher risk of
developing major cardiac events compared with those without risk
factors.31 Myrehaug et al5 found that having risk factors such as
diabetes or a history of smoking were predictive for cardiac
hospitalization in adult HL survivors. Because of the design of our
study (case-control rather than prospective follow-up), we could
not adequately examine the temporal relation between car-
diovascular risk factors and development of CHD. However, our
Table 3. Risk of Coronary Heart Disease According to Classic Cardiovascular Disease Risk Factors
Risk Factor
No. of Cases
(n = 325)
No. of Controls
(n = 1,204)
Crude
P
Adjusted*
PRR 95% CI RR 95% CI
Diabetes mellitus 11 38 1.11 0.56 to 2.22 .761 1.11 0.55 to 2.26 .764
Hypercholesterolemia 31 89 1.31 0.85 to 2.03 .225 1.07 0.68 to 1.69 .756
Hypertension 54 122 1.81 1.26 to 2.59 .001 1.86 1.29 to 2.68 .001
At least one of the above risk factors 80 213 1.57 1.15 to 2.13 .004 1.54 1.13 to 2.10 .006
Obesity (BMI $ 30)
At HL diagnosis 16 33 1.60 0.87 to 2.98 .131 1.89 0.99 to 3.59 .053
At cutoff 106 288 1.53 1.16 to 2.01 .002 1.64 1.24 to 2.16 , .001
Smoking at time of HL diagnosis 195 644 1.13 0.73 to 1.76 .571 1.01 0.53 to 1.93 .963
Smoking at cutoff 93 321 1.09 0.63 to 1.87 .758 1.19 0.70 to 2.03 .508
Ever smoked 236 818 1.27 0.95 to 1.71 .108 1.32 0.98 to 1.78 .067
Recent smoker at cutoff (, 5 years) 109 350 1.43 1.05 to 1.96 .024 1.56 1.13 to 2.15 .007
Physical activity at time of questionnaire†
Not active (, 1 h/wk) 14 22 1.00 0.48 to 2.06 1.00 0.46 to 2.17
Moderately active (1-3 h/wk) 35 70 0.83 0.53 to 1.30 0.72 0.45 to 1.17
Very active ($ 4 h/wk) 34 66 0.74 0.47 to 1.16 .484‡ 0.52 0.32 to 0.83 .136‡
Family history of coronary heart diseases†§ 31 30 2.36 1.28 to 4.34 .006 2.87 1.41 to 5.88 .004
NOTE. Patients were classified as having a risk factor if these were mentioned in the medical record or questionnaires and diagnosed before coronary heart disease/
cutoff date. If no risk factors were ever mentioned, patients were classified as not having a risk factor. Boldface indicates statistically significant RRs.
Abbreviations: BMI, body mass index (kg/m2); HL, Hodgkin lymphoma; RR, rate ratio.
*Adjusted for mediastinal radiotherapy and the other risk factors in case of separate estimates for diabetes mellitus, hypertension, hypercholesterolemia, and obesity.
†Analyzed unconditionally on a subpopulation of patients who filled in the risk factor questionnaire (84 patients and 158 individual controls), adjusted for the matching
factors.
‡P for trend.
§Family history based on (medical) first-degree family members (father, mother, brother, sister, son, or daughter).
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Fig 3. Cumulative incidence for different
ages at the time of Hodgkin lymphoma (HL)
treatment. Cumulative risks of coronary heart
disease (CHD) as first cardiac event among
5-year survivors of HL by time since initial HL
treatment for categories of mean heart dose
(Gy). Cumulative risks were calculated with
other heart disease or death as a competing
risk. (A) Cumulative incidence of CHD in HL
survivors treated before age 27.5 years. (B)
Cumulative incidence of CHD in HL survivors
treated between ages 27.5 and 36.4 years.
(C) Cumulative incidence of CHD in HL survi-
vors treated between ages 36.5 and50.9 years.
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analyses, excluding risk factor information obtained around CHD
diagnosis or corresponding cutoff date for controls, show that
hypertension is an important risk factor for CHD. Additional
analyses also including risk factors diagnosed around the time of
CHD diagnosis or corresponding cutoff date showed that not only
hypertension, but also hypercholesterolemia and diabetes are
associated with an increased risk of CHD, but this observation may
result from rigorous assessment of CHD risk factors at CHD
diagnosis in cases and not in controls.
To our knowledge, we are the first to show that higher
current physical activity levels may decrease CHD risk in adult HL
survivors. Jones et al32 recently found a lower risk of treatment-
related cardiac events in childhood cancer survivors who reported
9 metabolic equivalent-hours per week21 or more, which is
equivalent to approximately 2 to 2.5 hours of cycling or walking,
or 1 to 1.5 hours of jogging or running. In this observational
study, we could not determine whether the association with CHD
was due to a causal effect of exercise or to reverse causation, in
which the development of cardiac problems causes individuals to
reduce the amount of exercise they perform. A randomized
intervention trial is needed to provide more insight into the
effects of physical activity on CHD risk in the HL population.
Nevertheless, our findings regarding both exercise and cardiac
risk factors, in combination with previous evidence regarding
cardiac risk factors, underline the importance of risk factor
control and maintenance or adoption of a healthy lifestyle after
HL treatment.
We only included patients who developed CHD as their first
cardiac event to evaluate the direct effect of HL treatment on CHD
risk and to avoid confusion with secondary consequences of
(treatment of) other heart diseases. In our recent cohort analysis,7
we did not find different associations between mediastinal radio-
therapy and first CHD risk versus any CHD risk.
The use of MHD on the basis of the cardiac volume within the
radiation fields might be considered a limitation compared with
more advanced dosimetry techniques, such as the use of substitute
CT data sets23 or matched deformable heart models.33 However,
the current method has been shown to be accurate and has
practical advantages.19 Compared with CT-based dosimetry, our
method is less time-consuming and no expert knowledge is
needed. More importantly, individual size and shape of the heart
are taken into account, whereas other dosimetry methods used in
retrospective studies on patients treated before the era of CT-based
radiotherapy planning generally use one or two standard anatomic
patients.
Unfortunately, our dosimetry method does not enable esti-
mation of the radiation dose to the coronary arteries. However,
Darby et al10 did estimate the radiation dose to the left anterior
descending coronary artery, but found the MHD to be a better
predictor of the rate of major coronary events than the mean dose
to the left anterior descending artery, as the dose to the coronary
arteries was an uncertain measure. The benefits of the currently
applied method therefore outweigh the lack of a dose to specific
substructures, especially because the location of the coronary event
was often unknown for our cases.
In conclusion, mean radiation dose to the heart is an
important risk factor for the development of CHD in HL survivors.
To our knowledge, we are the first to show a linear radiation dose-
response relationship for CHD in HL survivors. This knowledge
may help clinicians to predict the risk of CHD in HL patients
treated today, as well as in survivors, and will assist in defining
appropriate follow-up care for HL survivors. Furthermore,
clinicians and patients should be aware of the importance of
controlling general cardiovascular disease risk factors and main-
taining a healthy lifestyle to reduce CHD risk.
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Appendix
Grading Criteria for Coronary Heart Disease
The conditions are graded (if possible, from the available information) according to the following criteria, adapted from the
Common Terminology Criteria for Adverse Events.
Ischemic or coronary heart disease (angina pectoris and myocardial infarction):
• Grade 1: Records do not confirm the diagnosis of coronary artery disease. This group includes patients with a clinical
diagnosis of angina pectoris but no other supporting information.
• Grade 2: Coronary artery disease confirmed by angiogram (but no acutemyocardial infarction or revascularization). Probable coronary
artery disease as evidenced by ischemic ECG changes (transient ST-segment depression and or T-wave flattening/inversion), imaging
studies (eg, positive stress test), or other indirect evidence (eg, letters from cardiologists to general practitioners and drug treatment).
• Grade 3: Evidence of nonfatal acute myocardial infarction, such as ECG, laboratory, or imaging report (angiogram,
echocardiogram, multigated acquisition). The patient is hemodynamically stable.
• Grade 4: The same as grade 3, but hemodynamically unstable or with life-threatening consequences (eg, severe hypotension,
heart failure, or ventricular fibrillation requiring emergency resuscitation or inotropic/balloon pump support). Coronary
revascularization (coronary artery bypass grafting or angioplasty/stenting).
Dosimetry Method
We outlined the cardiac contour on the Hodgkin lymphoma simulation radiographs. The percentage cardiac contour within
the field (%CCWF) was estimated by dividing the surface of the cardiac contour within the field by the surface of the total cardiac
contour, multiplied by 100. The %CCWF was multiplied by a correction factor of 1.12 to obtain the %CCWF.19 The prescribed
radiation dose to the mediastinum was converted to the equivalent dose in 2-Gy fractions, and the alpha-beta ratio was assumed to
be 2 Gy for late cardiac effects.26 The equivalent dose in 2-Gy was multiplied by the %CCWF to obtain the mean heart dose (MHD)
in Gy. The MHD was multiplied by 1.10 or 1.05 for patients who received para-aortic radiotherapy with or without splenic
radiotherapy, respectively.19 Patients who received para-aortic radiotherapy with or without splenic radiotherapy, but no
mediastinal radiotherapy, were assigned a MHD of 4 and 2 Gy, respectively, based on previous dosimetric findings.19
Table A1. Characteristics of Case-Defining Events
No. with AP % No. with MI %
Total
No. %
Total 140 100 185 100 325 100
Grade
2 140* 100 — 140 43.1
3 — 118 63.8 118 36.3
4 — 36 19.5 36 11.1
5 — 31 16.7 31 9.5
Treatment†
Drug therapy 28 20.0 34 18.4 62 19.1
PCI 41 29.3 48 25.9 89 27.4
CABG 54 38.6 13 7.0 67 20.6
None — 14‡ 7.6 14 4.3
Unknown 17 12.1 76§ 41.1 94 28.9
Death
Deceased at end of follow-up 56 40.0 113 61.1 169 52.0
Death due to cardiac cause 16 28.6 56 49.5 72 42.6
Death due to other malignancy 11 19.6 22 19.5 33 19.5
Death due to other causes 7 12.5 15 13.3 22 13.0
Unknown cause of death 22 39.3 20 17.7 42 24.9
Abbreviations: AP, angina pectoris; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*Of whom 95 required PCI or CABG.
†Treatment variables are not mutually exclusive.
‡Of whom 12 had grade 5 coronary heart disease.
§Of whom 16 had grade 5 coronary heart disease.
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Table A2. Sensitivity Analyses of Treatment-Related Associations
Treatment Factor
No. of Cases
(Total = 220)
No. of Controls
(Total = 836)
Crude
P
Adjusted*
PRR 95% CI RR 95% CI
Mean heart dose, Gy
0 17 160 1.00 0.60 to 1.66 1.00 0.60 to 1.68
1-4 12 93 1.19 0.65 to 2.19 1.13 0.62 to 2.09
5-14 16 64 2.52 1.45 to 4.37 2.48 1.43 to 4.32
15-19 39 130 2.89 2.02 to 4.15 2.80 1.95 to 4.02
20-24 65 186 3.49 2.63 to 4.62 3.32 2.51 to 4.40
25-34 67 183 3.85 2.87 to 5.15 3.63 2.69 to 4.89
35-45 4 20 2.29 0.77 to 6.79 , .001† 2.20 0.74 to 6.51 , .001†
NOTE. Unimputed data. Unconditional analyses were performed and therefore were adjusted for matching factors (age at Hodgkin lymphoma diagnosis, sex, and year
of Hodgkin lymphoma diagnosis). Included only patients for whom amean heart dose could be calculated, based on available prescribed dose and simulation radiographs
(220 cases and 836 controls). Boldface indicates significanlty increased RRs.
Abbreviations: RR, rate ratio.
*Mean heart dose was adjusted for chemotherapy.
†P for trend.
Table A3. Classic Risk Factors, Including Those Diagnosed Around and After Diagnosis of CHD/Cutoff Date and Risk of CHD
Risk factor
No. of Cases
(Total = 325)
No. of Controls
(Total = 1,204)
Crude Adjusted*
RR 95% CI P RR 95% CI P
Diabetes mellitus 66 149 1.92 1.38 to 2.67 , .001 1.98 1.41 to 2.77 , .001
Hypercholesterolemia 154 363 2.17 1.67 to 2.82 , .001 2.08 1.60 to 2.72 , .001
Hypertension 139 407 1.47 1.15 to 1.89 .003 1.52 1.18 to 1.96 .001
At least one of the above risk factors 261 769 2.36 1.74 to 3.22 ,.001 2.51 1.84 to 3.44 , .001
NOTE. Patients were classified as having a risk factor if these were mentioned in the medical record or questionnaires. If no risk factors were ever mentioned, patients
were classified as not having a risk factor. Boldface indicates significanlty increased RRs.
Abbreviations: CHD, coronary heart disease; RR, rate ratio.
*Adjusted for mediastinal radiotherapy and the other risk factors in case of separate estimates for diabetes mellitus, hypertension, and hypercholesterolemia.
Table A4. Excess Relative Risks per Gray Mean Heart Dose for Relevant Subgroups
ERR (%) 95% CI Pinteraction
Men 7.4 3.0 to 15.8
Women 7.2 0.7 to 34.4 . .5
Follow-up time of 5-14 years 6.4 1.2 to 18.9
Follow-up time of 15-29 years 8.1 2.7 to 20.6
Follow-up time of 30-43 years 7.8 20.7 to 73.5 . .5
Treated before age 27.5 20.0 5.4 to 70.5
Treated between ages 27.5 and 36.4 8.8 2.6 to 22.9
Treated between ages 36.5 and 50.9 4.2 0.6 to 11.1 .149
No chemotherapy 8.6 3.9 to 16.9
Chemotherapy 7.1 3.0 to 14.4 .380
No classic risk factors 7.0 2.8 to 15.1
$ 1 classic risk factor 9.7 1.3 to 44.5 . .5
Non-recent smoker 14.8 25.3 to 53.4
Recent smoker 8.0 231.7 to 24.4% .467
Abbreviations: ERR, excess relative risk.
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